StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Tuesday. The brokerage issued a sell rating on the stock.
Navidea Biopharmaceuticals Price Performance
NYSE:NAVB opened at $0.04 on Tuesday. The stock has a market cap of $3.50 million, a P/E ratio of -0.58 and a beta of 1.13. The business’s 50-day moving average price is $0.04 and its two-hundred day moving average price is $0.05. Navidea Biopharmaceuticals has a twelve month low of $0.02 and a twelve month high of $0.19.
Navidea Biopharmaceuticals Company Profile
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- What is the FTSE 100 index?
- Garmin Navigates to New Highs Driven By Wearables Trend
- What is MarketRankā¢? How to Use it
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Compound Interest and Why It Matters When Investing
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.